Healthcare Etf: A Detailed Look for Value-Focused Investors
A healthcare ETF gives you exposure to one of the largest sectors in the global economy through a single ticker, but not all healthcare ETFs are the same. The holdings differ, the concentration differs, the expense ratios differ, and the underlying quality of the businesses differs more than most investors expect when they assume "healthcare" is a monolithic category. For value-focused investors who care about what they actually own, the selection decision matters.
The U.S. healthcare sector represents roughly 13% of the S&P 500 by market capitalization as of April 2026 and spans four distinct business models: managed care (health insurers like UNH and Humana), pharmaceutical manufacturers (JNJ, PFE, MRK), medical device companies (MDT, ABT), and healthcare services and technology. Each sub-sector carries different margin structures, growth rates, regulatory exposure, and capital intensity. A healthcare ETF bundles all of them together, which means understanding the weights inside the fund is more important than reading the marketing description on the fund page.
Key Takeaways
- The three most widely held U.S. healthcare ETFs are XLV (Health Care Select Sector SPDR), VHT (Vanguard Health Care ETF), and IHF (iShares U.S. Healthcare Providers ETF), each with materially different holdings and concentration.
- XLV holds roughly 60 companies and gives 25-30% weight to its top three holdings; VHT holds over 400 companies and is more diversified across market caps.
- UnitedHealth (UNH) typically sits as the top or second-largest holding in most broad healthcare ETFs, giving those funds significant Medicare Advantage and medical cost ratio exposure.
- Healthcare ETF median P/E sits near 22.4 across the sector, but managed care names trade near 18-20x while biotech names can carry no P/E at all if unprofitable.
- Johnson & Johnson (JNJ), at a P/E near 15.4 and a dividend yield of 3.1% with 60+ consecutive years of dividend increases, anchors the value end of most healthcare ETF holdings.
- Expense ratios range from 0.09% (VHT) to 0.40% (sector-specific healthcare ETFs), a difference that compounds meaningfully over a 10-year holding period.
How the Major Healthcare ETFs Differ
Three funds dominate the healthcare ETF landscape by assets under management.
XLV tracks the Health Care Select Sector Index, which holds only S&P 500 healthcare companies. That constraint limits it to roughly 60 large-cap names and makes it the most concentrated of the three. Top holdings as of April 2026 include UNH, LLY (Eli Lilly), JNJ, ABBV (AbbVie), and MRK (Merck), which together account for roughly 40% of fund assets.
VHT tracks the MSCI US Investable Market Health Care 25/50 Index. It holds over 400 companies including mid-cap and small-cap names that XLV excludes. This makes VHT a broader representation of the sector, with more exposure to biotech companies that carry higher growth potential and higher risk. The top holdings overlap with XLV, but the tail of smaller names adds diversification that XLV does not offer.
IHF focuses specifically on healthcare providers, managed care, and pharmacy benefit managers. It is more concentrated in the insurance and services sub-sector than either XLV or VHT. This makes IHF a more precise tool if your thesis is specifically about managed care economics, but a less appropriate holding if you want broad healthcare exposure.
| Fund | Holdings | Expense Ratio | AUM (approx.) | Top Holding Weight | Dividend Yield |
|---|---|---|---|---|---|
| XLV | ~60 | 0.09% | $42B | UNH ~12% | 1.6% |
| VHT | ~400+ | 0.09% | $18B | LLY ~9% | 1.4% |
| IHF | ~40 | 0.42% | $2.1B | UNH ~18% | 0.9% |
| FHLC | ~490 | 0.08% | $4.2B | LLY ~10% | 1.5% |
| IBB | ~250 | 0.44% | $8.3B | AMGN ~9% | 0.8% |
IBB is a Nasdaq Biotechnology ETF rather than a pure healthcare ETF, but it appears in the same searches because many investors use it as a healthcare-adjacent position. Its expense ratio is higher and its volatility is substantially greater than broad healthcare funds, reflecting the binary risk profile of biotech development stage companies.
The Quality of What You Own Inside a Healthcare ETF
Buying a healthcare ETF is buying a basket of businesses. The question is whether those businesses are good ones. Running the top 20 holdings of XLV through our screener reveals a mixed picture by value investor standards.
The managed care names (UNH, CI, HUM) screen well on ROIC and FCF margin but carry moderate debt relative to earnings. The large pharmaceutical names (JNJ, MRK, PFE) screen well on Piotroski F-Score because of their consistent profitability and balance sheet strength, but growth rates are uneven; Pfizer's post-COVID revenue decline is a specific data point that depresses the sector aggregate.
Medical device companies (MDT, ABT, SYK) typically carry ROIC in the 12-18% range and steady free cash flow margins near 15-20%. They represent the most predictable sub-sector from an investor perspective because the recurring revenue from replacement procedures and consumables smooths revenue curves.
Biotech and specialty pharma names inside VHT's tail carry the most variance. Some are pre-revenue with no earnings to analyze. Others have single-product revenues concentrated in one therapy area with patent cliffs that create binary outcomes over five-year horizons.
UnitedHealth's Weight Problem for Healthcare ETF Investors
Because UNH is both the largest company in the Dow Jones Industrial Average by price weight and typically the largest or second-largest company in major healthcare ETFs by market cap, investors who hold both a broad market ETF and a healthcare ETF end up with significant UNH concentration.
An investor holding VTI (total U.S. market) plus XLV for healthcare overweight will find UNH appearing in both positions. The combined effective weight can exceed 2-3% of total portfolio value, which is meaningful for a single company exposed to Medicare Advantage reimbursement risk and periodic regulatory scrutiny.
This is not a reason to avoid healthcare ETFs, but it is a reason to check your total portfolio exposure before adding a sector fund on top of an existing broad market position. The solution is either to use the sector ETF to replace rather than add to existing healthcare exposure, or to choose a fund like VHT whose more diversified holdings dilute the UNH concentration.
Dividends and Income Characteristics
Healthcare ETFs are not high-yield income vehicles, but they are more income-oriented than technology ETFs. XLV's dividend yield near 1.6% comes primarily from the pharmaceutical and consumer healthcare names within the fund. JNJ's 3.1% yield and 60+ year dividend growth streak, Merck's 2.8% yield, and AbbVie's 3.4% yield all contribute to the aggregate payout.
Dividend growth, rather than current yield, is the more relevant metric for long-term investors. Healthcare companies with durable business models tend to grow dividends consistently because their revenue streams are recurring and their pricing power over time has historically exceeded general inflation in most periods.
Coca-Cola (KO) at a yield of 3.0% is the traditional reference point for consumer staples dividend compounders. JNJ plays a similar role in healthcare: the 15.4x P/E and the 3.1% yield represent a market that is pricing in modest growth but high dividend reliability. An ETF with JNJ as a top-five holding inherits some of that compounding characteristic.
Regulatory Risk Across the Healthcare Sub-Sectors
All healthcare ETFs carry regulatory risk, but the nature of that risk varies by sub-sector.
Managed care names are subject to CMS rate-setting for Medicare Advantage. A below-expected rate announcement can move UNH down 5-8% in a single session, which cascades into XLV and VHT given their weighting.
Pharmaceutical names face drug pricing legislation risk. The Inflation Reduction Act created the first framework for Medicare drug price negotiation, targeting ten drugs initially with the list expanding each year through 2030. Companies with large Medicare-facing drug portfolios carry measurable revenue risk from these negotiations.
Medical devices face reimbursement risk from CMS coverage decisions and periodic FDA reauthorization cycles. These tend to be smaller in magnitude and more predictable in timing than managed care or pharma regulatory events.
The Piotroski F-Score is useful here not because it predicts regulatory outcomes but because companies with high F-Scores (7-9 out of 9) have the financial strength to absorb regulatory headwinds without existential balance sheet stress. Weak-balance-sheet healthcare companies facing adverse regulatory events are where the serious permanent capital loss cases tend to concentrate.
How to Use a Healthcare ETF in a Value Portfolio
A healthcare ETF serves three distinct purposes in a value portfolio.
The first is diversified sector exposure when you believe healthcare is undervalued relative to the market but do not have conviction on specific names. In this case, XLV or VHT gives you broad exposure with low cost and reasonable liquidity.
The second is a complement to single-stock positions. If you own JNJ and UNH individually because you have done the fundamental work, a broad healthcare ETF adds redundant exposure you probably do not need.
The third is a defensive anchor. Healthcare demand is relatively inelastic; people need medical care regardless of economic conditions. During recessions, healthcare ETFs have historically held value better than cyclical sectors. XLV fell about 14% during the 2022 bear market while the Nasdaq-100 fell 33%.
Run the specific stocks inside any healthcare ETF you are considering through our screener before buying. The fund fact sheet tells you the ticker list. The screener tells you what the fundamentals actually look like.
Further reading: Investopedia · CFA Institute
Why healthcare sector ETF comparison Matters
This section anchors the discussion on healthcare sector ETF comparison. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply healthcare sector ETF comparison in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for healthcare sector ETF comparison
See the main discussion of healthcare sector ETF comparison in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using healthcare sector ETF comparison alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for healthcare sector ETF comparison
See the main discussion of healthcare sector ETF comparison in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using healthcare sector ETF comparison alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Piotroski F-Score — Piotroski F-Score captures the reliability of reported earnings versus underlying cash flow
- Free Cash Flow Margin (FCF Margin) — Free Cash Flow Margin measures how efficiently a company converts capital into earnings
- ROIC Consistency — ROIC Consistency measures how efficiently a company converts capital into earnings
- United Healthcare Stock Price — related ValueMarkers analysis
- Dow Jones — related ValueMarkers analysis
- Is Operating Income The Same As Ebit — related ValueMarkers analysis
Frequently Asked Questions
why is united healthcare stock dropping
UnitedHealth stock tends to drop when the company reports a medical loss ratio above expectations, when CMS announces below-market Medicare Advantage reimbursement rates, or when legislative proposals targeting health insurer profitability or pharmacy benefit manager practices gain traction. In 2024, elevated care utilization across the managed care sector pushed MLRs above guidance, which caused a sector-wide decline. Individual news events specific to UNH, such as regulatory investigations or management changes, can also drive single-day declines independent of broader sector moves.
canary capital xrp etf
The Canary Capital XRP ETF is a proposed spot ETF holding XRP, a cryptocurrency. It is unrelated to healthcare ETF investing. Canary Capital filed for the XRP ETF with the SEC in late 2024, and the approval process follows the same regulatory path as other cryptocurrency ETF applications. This product would hold digital assets rather than healthcare equities and carries an entirely different risk profile from any healthcare ETF.
canary xrp etf approval
The Canary XRP ETF approval status depends on SEC review timelines, which have varied significantly across cryptocurrency ETF applications. The SEC approved spot Bitcoin ETFs in January 2024 after years of rejections. XRP faces additional regulatory complexity from the Ripple Labs lawsuit, which was largely resolved in mid-2023 but created lingering uncertainty about XRP's regulatory classification. These approval dynamics are entirely separate from the healthcare ETF market and irrelevant to healthcare investing decisions.
is vug considered a growth etf
VUG (Vanguard Growth ETF) is a large-cap growth ETF, not a healthcare ETF. It tracks the CRSP US Large Cap Growth Index and holds companies with high earnings growth rates, high price-to-book ratios, and strong analyst earnings growth forecasts. VUG's top holdings are typically Apple, Nvidia, Microsoft, Amazon, and Meta. While VUG does hold some healthcare companies like Eli Lilly and UnitedHealth, they represent a small fraction of the fund compared to technology and consumer discretionary weights.
how to invest in healthcare stocks
The two most practical approaches are through a healthcare ETF like XLV or VHT for diversified exposure, or through individual stock research targeting names with durable competitive advantages and attractive valuations. Individual stock selection requires understanding the sub-sector dynamics: managed care margins, pharmaceutical patent timelines, medical device reimbursement cycles, and biotech pipeline risk. For investors new to the sector, starting with an ETF to build familiarity, then selectively adding individual names as conviction develops, is a reasonable progression. Our screener lets you filter healthcare stocks by ROIC, FCF margin, and Piotroski F-Score to identify the strongest-quality names within the sector.
is voo an etf
VOO (Vanguard S&P 500 ETF) is a broad-market ETF tracking the S&P 500, not a healthcare ETF. It holds all 500 companies in the S&P 500 weighted by market capitalization. Healthcare stocks represent roughly 13% of VOO's holdings, which means owning VOO gives you indirect healthcare exposure without a dedicated sector position. Investors who want more healthcare exposure than VOO provides can add a healthcare ETF alongside it, understanding that the top healthcare names will appear in both funds.
Find healthcare ETFs and individual healthcare stocks with the quality filters that matter: ROIC consistency, FCF margin, and Piotroski F-Score. Start your analysis in our screener.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.